Paul Stoffels, Galapagos CEO (Andrew Harnik/AP Images)

CAR-T in, IPF drug out: Gala­pa­gos bails on biotech part­ner­ship amid pipeline re­vamp

It turns out that Paul Stof­fels’ new plans for Gala­pa­gos don’t just in­volve buy­ing new things. The John­son & John­son R&D vet — and new biotech CEO — is al­so clear­ing out the at­tic.

Gala­pa­gos is re­turn­ing rights to a dual chiti­nase in­hibitor it had li­censed back in 2020 from Mol­e­cure, a War­saw, Poland-based small mol­e­cule drug de­vel­op­er then known as On­coAren­di, for €25 mil­lion up­front.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.